Exhibit 99.1 Pursuant to General Instruction number 5(b)(v) to Form 3, the following additional reporting persons are covered by this joint filing: Name: Foresite Capital Fund II, L.P. Foresite Capital Management III, LLC Foresite Capital Fund III, L.P. Address: Foresite Capital 600 Montgomery Street Street Suite 4500 San Francisco, CA 94111 Name: James B. Tananbaum Address: 3052 Pacific Avenue San Francisco, CA 94115 Designated Filer: Foresite Capital Management II, LLC Issuer and Ticker Symbol: Aerie Pharmaceuticals, Inc. (AERI) Date of Event Requiring Statement:July 22, 2016 Each of the following is a Joint Filer with Foresite Capital Management II, LLC ("FCM II") and may be deemed to share indirect beneficial ownership in the securities set forth on the attached Form 3: FCM II is the general partner of Foresite Capital Fund II, L.P. ("FCF II"). As such, FCM II possesses sole voting and investment control over the shares owned by FCF II, and may be deemed to have indirect beneficial ownership of the securities held by FCF II, however, owns no shares of the Issuer directly. Mr. Tananbaum is the managing member of FCM II and in his capacity as such, may be deemed to exercise sole voting, investment and dispositive power over the shares held by FCF II. FCM III is the general partner of Foresite Capital Fund III, L.P. ("FCF III"). As such, FCM III possesses sole voting and investment control over the shares owned by FCF III, and may be deemed to have indirect beneficial ownership of the securities held by FCF III, however, owns no shares of the Issuer directly. Mr. Tananbaum is the managing member of FCM III and in his capacity as such, may be deemed to exercise sole voting, investment and dispositive power over the shares held by FCF III. Each Reporting Person disclaims beneficial ownership of the shares held by FCF II and FCF III except to the extent of his or its proportionate pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, or otherwise, any of the Reporting Persons are the beneficial owners of all of the equity securities covered by this statement. Each of the Reporting Persons listed above hereby designates FCM II as its designated filer of Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder. FORESITE CAPITAL MANAGEMENT II, LLC By: /s/ Dennis D. Ryan -------------------------------- Dennis D. Ryan Chief Financial Officer FORESITE CAPITAL FUND II, L.P By: Foresite Capital Management II, LLC Its General Partner By: /s/ Dennis D. Ryan -------------------------------- Dennis D. Ryan Chief Financial Officer FORESITE CAPITAL MANAGEMENT III, LLC By: /s/ Dennis D. Ryan -------------------------------- Dennis D. Ryan Chief Financial Officer FORESITE CAPITAL FUND III, L.P By: Foresite Capital Management III, LLC Its General Partner By: /s/ Dennis D. Ryan -------------------------------- Dennis D. Ryan Chief Financial Officer /s/ James B. Tananbaum ---------------------------------------- James B. Tananbaum
- Company Dashboard
- Filings
- Holdings
-
3 Filing
Foresite Capital Management III Form 3AERIE PHARMACEUTICALS / James B. Tananbaum ownership change
Filed: 26 Jul 16, 12:00am